DSP-0390

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma, Malignant

Conditions

Glioma, Malignant, Grade II Glioma, IDH Mutation

Trial Timeline

Apr 3, 2025 → May 17, 2026

About DSP-0390

DSP-0390 is a phase 1 stage product being developed by Sumitomo Pharma for Glioma, Malignant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06636162. Target conditions include Glioma, Malignant, Grade II Glioma, IDH Mutation.

What happened to similar drugs?

0 of 3 similar drugs in Glioma, Malignant were approved

Approved (0) Terminated (0) Active (3)
🔄Everolimus + ONC201Jazz PharmaceuticalsPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄safusidenib + PlaceboNuvation BioPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06636162Phase 1Recruiting
NCT05023551Phase 1Active

Competing Products

20 competing products in Glioma, Malignant

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
15
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
LY2157299 + LomustineEli LillyPhase 1
29
DS-1001bDaiichi SankyoPhase 2
39
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
32
Temozolomide and BevacizumabEisaiPhase 2
31
TemozolomideEisaiPhase 2
31
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Palonosetron (PALO)EisaiPhase 2
35
Gliadel/Avastin/CPT-11EisaiPhase 2
27
Lenvatinib + BevacizumabEisaiPhase 2
35
Granisetron + OndansetronKyowa KirinPhase 2
27
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EnzastaurinEli LillyPhase 2
35
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
32
Abemaciclib + TemozolomideEli LillyPhase 2
39
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
31